Pipeline wins in gastrointestinal oncology ease the 2028 patent cliff
- JAKAFI generated $826.5 million in Q3 2026, driving the bulk of total revenue.
- New early stage trial data in pancreatic and colorectal cancer showed strong response rates.
- The company discontinued a clinical trial for ovarian cancer to focus on earlier treatment lines.
- New generic drug challengers have filed applications against JAKAFI.
- Povorcitinib received a positive regulatory opinion in Europe for treating a chronic skin condition.
A race before 2028
Incyte is racing to build its next generation of products before its primary drug faces a major hurdle. JAKAFI brings in most of the money today. Its U.S. patent protection is the key issue because exclusivity is expected to end in 2028, opening the door for generic competition.
The bull case is gaining traction due to maturing pipeline assets. Strong early trial results for new gastrointestinal oncology drugs in pancreatic and colorectal cancer help reduce the risk of a severe drop in future revenue. This adds to the momentum of OPZELURA and a pending U.S. approval for povorcitinib by early 2027.
The bear case centers on the sheer size of the revenue gap that must be filled. The company recently discontinued a late stage ovarian cancer trial, proving that pipeline attrition is a constant threat. Furthermore, new generic challengers continue to file applications against JAKAFI, keeping legal risks high.
Finn notes a balanced view. The core business is generating strong cash flow, but the race to commercialize new blockbuster drugs before 2028 will dictate the long term value of the stock.
Drug sales plus partner royalties
Incyte discovers, develops, and sells prescription drugs. It focuses mainly on hematology and oncology, which means blood diseases and cancer, plus inflammation and autoimmunity, which includes skin disease.
Most of the business comes from direct product sales. In Q3 2026, total revenue was $1.55 billion. JAKAFI net sales were $826.5 million. The inflammation segment generated $254.9 million in net product revenues, driven almost entirely by OPZELURA.
Incyte also gets royalty revenue from partners. Novartis sells JAKAVI outside the U.S., Lilly sells OLUMIANT, and Novartis sells TABRECTA. Total royalty revenue was $191.0 million in Q3 2026.
The model works best when patents keep copycat drugs away and payers cover the drugs at good prices. It breaks if generic competition arrives early, if reimbursement gets tougher, or if pipeline drugs miss key trials.
The drugs that matter
JAKAFI
JAKAFI is the anchor drug for myelofibrosis, polycythemia vera, and graft-versus-host disease. It produced $826.5 million of Q3 2026 net sales.
OPZELURA
OPZELURA is a topical ruxolitinib cream for atopic dermatitis and vitiligo. It is the primary driver of the inflammation and autoimmunity segment.
GI Oncology Pipeline
New assets 734 and 890 have shown high response rates in pancreatic and colorectal cancers, providing a potential post-JAKAFI growth avenue.
Povorcitinib
Povorcitinib is an oral JAK1 inhibitor with an accepted FDA filing for hidradenitis suppurativa and a recent positive regulatory opinion in Europe.
JAKAFI XR
Approved in May 2026, this extended release tablet offers a new treatment option for intermediate or high risk myelofibrosis and other conditions.
Latarcibart
Acquired through the Vega transaction, this Phase III asset targets von Willebrand disease and represents a potential new growth franchise.
Partnered royalties
Incyte earns royalties from drugs sold by partners, including JAKAVI, OLUMIANT, and TABRECTA. Royalty revenue was $191.0 million in Q3 2026.
Q3 2026 revenue relies heavily on JAKAFI
This mix uses Incyte’s Q3 2026 revenue disclosure for the three months ended September 30, 2026, reflecting total revenues of $1.55 billion.
What could break the story
JAKAFI patent cliff
High impact · High oddsJAKAFI is the largest revenue source, with $826.5 million of Q3 2026 net sales. The key U.S. exclusivity issue is 2028, and several generic challengers remain active, including new filers like Alembic and MSN. If copycat drugs arrive sooner or take share faster than expected, cash flow will fall rapidly.
OPZELURA generic challenges
High impact · Medium oddsOPZELURA is one of Incyte’s main growth drivers, but multiple companies have filed applications seeking approval for generic versions. A loss in court or a weak settlement would reduce the value of a key post-JAKAFI product.
Clinical pipeline failures
Medium impact · Medium oddsThe recent discontinuation of the CDK2 asset in ovarian cancer shows the inherent difficulty of drug development. If other late stage assets fail in larger Phase 3 trials, long term growth will suffer.
Povorcitinib launch gap
Medium impact · Medium oddsPovorcitinib looks promising with a positive European regulatory opinion and an accepted U.S. filing. But trial success does not guarantee approval, payer access, or fast adoption. If U.S. approval slips past Q1 2027, the revenue bridge gets weaker.
In one breath
What does Incyte do?
Incyte makes prescription drugs for cancer, blood diseases, and immune conditions. Its biggest drug is JAKAFI, while OPZELURA is its main dermatology growth product.
Why is JAKAFI so important to Incyte stock?
JAKAFI is the main cash generator, with $826.5 million of Q3 2026 net sales. The worry is that U.S. patent exclusivity is expected to end in 2028, which could bring generic competition.
What is the biggest upside catalyst for Incyte?
Povorcitinib and the new gastrointestinal oncology pipeline are the biggest catalysts. Povorcitinib has an accepted FDA filing in hidradenitis suppurativa, with more regulatory steps expected through Q1 2027.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Incyte Corporation in Finn's Biotechnology industry ranking.

